Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18726992 | 0.86 | SMN1; SMN2 (0.42) | SMN1; SMN2HTR1AADRA1AADRA1B | |
| SCHEMBL15692961 | 0.77 | HTR1A (0.30) | HTR1AADRA1B | |
| SCHEMBL15692810 | 0.77 | LMNA (0.36) | HTR1AADRA1AADRA1B | |
| SCHEMBL15692870 | 0.73 | — | — | |
| SCHEMBL18727619 | 0.73 | SMN1; SMN2 (0.34) | SMN1; SMN2 | |
| SCHEMBL15692866 | 0.73 | ADRA1A (0.35) | HTR1AADRA1AADRA1B | |
| SCHEMBL15746325 | 0.72 | SMN1; SMN2 (0.36) | SMN1; SMN2HTR1AADRA1AADRA1B | |
| SCHEMBL17208933 | 0.70 | DRD4 (0.35) | — | |
| SCHEMBL18020317 | 0.69 | CYP11B2 (0.35) | — | |
| SCHEMBL15692845 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9303061-B2 | Spiro compounds as Hepatitis C virus inhibitors | Sunshine Luke Pharma Co., Ltd. (CN) | 2016-04-05 | — | — | US | disclosed |
| US-20140147412-A1 | SPIRO COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2014-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140147412-A1 | SPIRO COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | HAVCR2, SORD, SLC10A1 | SMN1; SMN2 2162/4885HTR1A 2833/4885ADRA1A 1794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.